EUR USD GBP
+353-1-416-8900REST OF WORLD
1-800-526-8630U.S. (TOLL FREE)

Alcohol Addiction - Pipeline Review, H1 2017

  • ID: 4091135
  • Report
  • February 2017
  • 124 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics LLC
  • Cerecor Inc
  • Curemark LLC
  • Euthymics Bioscience Inc
  • Indivior Plc
  • MORE
Alcohol Addiction - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides an overview of the Alcohol Addiction (Central Nervous System) pipeline landscape.

Alcohol addiction refers to a psychological and physical dependency on alcohol. Symptoms include decreased involvement in extracurricular activities, depression, restlessness, inability to control drinking and violent behavior. Risk factors include age, family history and depression and other mental health problems.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Alcohol Addiction - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Alcohol Addiction (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Alcohol Addiction (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Alcohol Addiction and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 3, 10, 1, 1, 16 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Alcohol Addiction (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Alcohol Addiction (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Alcohol Addiction (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Alcohol Addiction (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Alcohol Addiction (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Alcohol Addiction (Central Nervous System).
Reasons to Buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Alcohol Addiction (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Alcohol Addiction (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Astraea Therapeutics LLC
  • Cerecor Inc
  • Curemark LLC
  • Euthymics Bioscience Inc
  • Indivior Plc
  • MORE
Introduction

Alcohol Addiction - Overview

Alcohol Addiction - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Alcohol Addiction - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Alcohol Addiction - Companies Involved in Therapeutics Development

AbbVie Inc

Addex Therapeutics Ltd

Adial Pharmaceuticals LLC

Astraea Therapeutics LLC

BioCorRx Inc

Bionex Pharmaceuticals LLC

Bioprojet SCR

Cerecor Inc

Chronos Therapeutics Ltd

Corcept Therapeutics Inc

Curemark LLC

Eli Lilly and Company

Ethypharm SA

Euthymics Bioscience Inc

H. Lundbeck A/S

Heptares Therapeutics Ltd

Indivior Plc

Kinnov Therapeutics SAS

Kyorin Pharmaceutical Co Ltd

Lohocla Research Corp

Omeros Corp

Pfizer Inc

Savant HWP Inc

SK Biopharmaceuticals Co Ltd

Tonix Pharmaceuticals Holding Corp

VM Discovery Inc

XenoPort Inc

Zynerba Pharmaceuticals Inc

Alcohol Addiction - Drug Profiles

(cyproheptadine hydrochloride + prazosin hydrochloride) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(disulfiram + selegiline) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

18-MC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

A-705253 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ABT-436 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ADX-71441 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amitifadine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

arbaclofen placarbil - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-1001 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AT-200 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baclofen - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

carisbamate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CERC-501 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-1212 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CTDP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs to Target HAT and HDAC for Alcohol Addiction and Anxiety Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gabapentin enacarbil ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GET-73 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ibudilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

JDTic - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

nalmefene - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

naltrexone hydrochloride SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

odelepran hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OMS-527 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ondansetron hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PF-05190457 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pitolisant - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-10406 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Agonize Oxytocin Receptor for Alcohol Addiction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Mu Opioid Receptor for Drug Abuse, Alcohol Addiction and OIC - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize NMDA Receptor and Block Sodium Channels for CNS disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize GABAA1 for Alcohol Addiction and Anxiety - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Glucocorticoid Receptor II for Alcohol Dependance - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VMD-2202 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Alcohol Addiction - Dormant Projects

Alcohol Addiction - Discontinued Products

Alcohol Addiction - Product Development Milestones

Featured News & Press Releases

Jan 23, 2017: MediciNova Announces Publication of Positive Findings on MN-166 (ibudilast) in Alcohol Dependence

Nov 28, 2016: BioCorRx Selects Covance for Non-Clinical Studies, Announces the Addition of Dr. Bal S. Brar to its Drug Development Team, Plans Pre-IND Meeting with FDA

Sep 15, 2016: BioCorRx Announces Update From First Joint Steering Committee Meeting for Injectable Naltrexone Product

Sep 03, 2016: Baclofen helps reduce the consumption of alcohol in alcohol - dependent patients

Aug 31, 2016: BioCorRx Announces BioCorRx Pharmaceuticals Subsidiary; Forms Joint Steering Committee for Injectable Naltrexone Technology

Jul 25, 2016: Cerecor Announces Research Grant from the Department of Defense to Study CERC-501 in Animal Models for Co-Morbid Post-Traumatic Stress Disorder and Alcohol Use Disorder

Jul 20, 2016: Cerecor Announces $1.0 Million Research & Development Grant from the National Institute on Alcohol Abuse and Alcoholism at the National Institutes of Health

Jul 14, 2016: BioCorRx Launches R&D Initiative to Pursue FDA Approval for Naltrexone Implant

Jun 29, 2016: MediciNova Announces Results from Clinical Trial of MN-166 (ibudilast) in Alcohol Dependence Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

May 25, 2016: MediciNova Announces Additional Results from the Completed Trial of MN-166 (ibudilast) in Alcohol Dependence to be Presented at the 39th Annual Scientific Meeting of the Research Society on Alcoholism in New Orleans, Louisiana

Jan 14, 2016: BioCorRx Announces New Agreements With Wellness Centers in Slidell, LA, Memphis and Nashville, TN, and Philadelphia, PA

Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor’s Oral Kappa Opioid Receptor Antagonist, CERC-501

Dec 09, 2015: MediciNova Announces Positive Findings From a Clinical Trial of MN-166 (ibudilast) in Alcohol Use Disorder (AUD) Reported at the American College of Neuropsychopharmacology (ACNP)'s 54th Annual Meeting

Dec 07, 2015: BioCorRx Announces Agreements With Additional Wellness Centers in California, Wisconsin and Arizona

Oct 13, 2015: Addex’ ADX71441 Demonstrates Robust Efficacy in Multiple Preclinical Models of Alcohol Use Disorder

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables:

Number of Products under Development for Alcohol Addiction, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Companies, H1 2017 (Contd..1), H1

Number of Products under Development by Universities/Institutes, H1

Products under Development by Companies, H1

Products under Development by Companies, H1 2017 (Contd..1), H1

Products under Development by Universities/Institutes, H1

Number of Products by Stage and Target, H1

Number of Products by Stage and Target, H1 2017 (Contd..1), H1

Number of Products by Stage and Mechanism of Action, H1

Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1

Number of Products by Stage and Route of Administration, H1

Number of Products by Stage and Molecule Type, H1

Alcohol Addiction - Pipeline by AbbVie Inc, H1

Alcohol Addiction - Pipeline by Addex Therapeutics Ltd, H1

Alcohol Addiction - Pipeline by Adial Pharmaceuticals LLC, H1

Alcohol Addiction - Pipeline by Astraea Therapeutics LLC, H1

Alcohol Addiction - Pipeline by BioCorRx Inc, H1

Alcohol Addiction - Pipeline by Bionex Pharmaceuticals LLC, H1

Alcohol Addiction - Pipeline by Bioprojet SCR, H1

Alcohol Addiction - Pipeline by Cerecor Inc, H1

Alcohol Addiction - Pipeline by Chronos Therapeutics Ltd, H1

Alcohol Addiction - Pipeline by Corcept Therapeutics Inc, H1

Alcohol Addiction - Pipeline by Curemark LLC, H1

Alcohol Addiction - Pipeline by Eli Lilly and Company, H1

Alcohol Addiction - Pipeline by Ethypharm SA, H1

Alcohol Addiction - Pipeline by Euthymics Bioscience Inc, H1

Alcohol Addiction - Pipeline by H. Lundbeck A/S, H1

Alcohol Addiction - Pipeline by Heptares Therapeutics Ltd, H1

Alcohol Addiction - Pipeline by Indivior Plc, H1

Alcohol Addiction - Pipeline by Kinnov Therapeutics SAS, H1

Alcohol Addiction - Pipeline by Kyorin Pharmaceutical Co Ltd, H1

Alcohol Addiction - Pipeline by Lohocla Research Corp, H1

Alcohol Addiction - Pipeline by Omeros Corp, H1

Alcohol Addiction - Pipeline by Pfizer Inc, H1

Alcohol Addiction - Pipeline by Savant HWP Inc, H1

Alcohol Addiction - Pipeline by SK Biopharmaceuticals Co Ltd, H1

Alcohol Addiction - Pipeline by Tonix Pharmaceuticals Holding Corp, H1

Alcohol Addiction - Pipeline by VM Discovery Inc, H1

Alcohol Addiction - Pipeline by XenoPort Inc, H1

Alcohol Addiction - Pipeline by Zynerba Pharmaceuticals Inc, H1

Alcohol Addiction - Dormant Projects, H1

Alcohol Addiction - Dormant Projects, H1 2017 (Contd..1), H1

Alcohol Addiction - Discontinued Products, H1

List of Figures:

Number of Products under Development for Alcohol Addiction, H1

Number of Products under Development by Companies, H1

Number of Products under Development by Universities/Institutes, H1

Number of Products by Top 10 Targets, H1

Number of Products by Stage and Top 10 Targets, H1

Number of Products by Top 10 Mechanism of Actions, H1

Number of Products by Stage and Top 10 Mechanism of Actions, H1

Number of Products by Routes of Administration, H1

Number of Products by Stage and Routes of Administration, H1

Number of Products by Molecule Types, H1

Number of Products by Stage and Molecule Types, H
Note: Product cover images may vary from those shown
3 of 4
  • AbbVie Inc
  • Addex Therapeutics Ltd
  • Adial Pharmaceuticals LLC
  • Astraea Therapeutics LLC
  • BioCorRx Inc
  • Bionex Pharmaceuticals LLC
  • Bioprojet SCR
  • Cerecor Inc
  • Chronos Therapeutics Ltd
  • Corcept Therapeutics Inc
  • Curemark LLC
  • Eli Lilly and Company
  • Ethypharm SA
  • Euthymics Bioscience Inc
  • H. Lundbeck A/S
  • Heptares Therapeutics Ltd
  • Indivior Plc
  • Kinnov Therapeutics SAS
  • Kyorin Pharmaceutical Co Ltd
  • Lohocla Research Corp
  • Omeros Corp
  • Pfizer Inc
  • Savant HWP Inc
  • SK Biopharmaceuticals Co Ltd
  • Tonix Pharmaceuticals Holding Corp
  • VM Discovery Inc
  • XenoPort Inc
  • Zynerba Pharmaceuticals Inc
Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown
Adroll
adroll